All In Biotech

Drug Trial Radar · NCT07220616

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC Targeting CD37, for Hematological Malignancies

Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

420

Planned (sponsor's estimate)

Start

Jan 16, 2026

Primary completion

Nov 30, 2030

Study completion Nov 30, 2030

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
Oct 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.

Conditions

  • Hematological Malignancies
  • B-cell Non-Hodgkin Lymphoma

Interventions

  • DS3790aDrug

    Administered as specified in the protocol

  • Combination drugDrug

    Administered as specified in the protocol

  • Combination drugDrug

    Administered as specified in the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Reporting Dose-limiting Toxicities, Treatment-emergent Adverse Events, Serious Adverse Events, Adverse Events of Special Interest, and Deaths in Participants With Hematological MalignanciesTime frame: Baseline up to 5 years
  2. Complete Response in Participants With Hematological Malignancies by Blinded Independent Central Review (Cohort A Randomization Optimization Phase, Cohort A Phase 2)Time frame: Baseline up to 5 years
  3. Complete Response in Participants With Hematological Malignancies by Investigator Assessment (Cohort B Randomization Optimization Phase)Time frame: Baseline up to 5 years

Locations

8 sites in 4 countries. Site status is shown where the registry gives one.

  • Research Site

    New York, New York · Recruiting

  • Research Site

    Lille, France · Recruiting

  • Research Site

    Pierre-Bénite, France · Recruiting

  • Research Site

    Villejuif, France · Recruiting

  • Research Site

    Bologna, Italy · Recruiting

  • Research Site

    Nagoya, Japan · Recruiting

  • Research Site

    Tokyo, Japan · Recruiting

  • Research Site

    Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.